Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(104 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
'''reviews & screen candidate compounds covid19'''
 
{{tp|p=32226821|t=2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases |pdf=|usr=}}
 
{{tp|p=32292689|t=ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods |pdf=|usr=}}
 
{{tp|p=32318328|t=ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 |pdf=|usr=}}
 
{{tp|p=32152082|t=2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus |pdf=|usr=}}
 
{{tp|p=32232214|t=2020. Potential Treatments for COVID-19; a Narrative Literature Review |pdf=|usr=}}
 
{{tp|p=32134278|t=2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32375268|t=2020. Coronavirus Pandemic-Therapy and Vaccines |pdf=|usr=}}
 
{{tp|p=31996494|t=2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV) |pdf=|usr=}}
 
{{tp|p=32334062|t=ä. Current status of potential therapeutic candidates for the COVID-19 crisis |pdf=|usr=}}
 
{{tp|p=32347359|t=ä. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19 |pdf=|usr=}}
 
{{tp|p=32162456|t=2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep  Docking of 1 3 Billion Compounds |pdf=|usr=}}
 
{{tp|p=32194980|t=2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32149769|t=ä. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model |pdf=|usr=}}
 
  
 +
*'''[[scouting ideas]]'''
  
'''Icatibant''' bradykinin antagonist
+
*'''[[PHA Biologicals]]'''
{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
+
  
'''Arbidol''' retarget influenza
+
*'''[[PHA conventional pharmacology]]'''
{{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}}
+
  
'''Macrolide antibiotics'''
+
*'''[[PHA retargeted compounds]]'''
{{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}}
+
  
'''Oleoylethanolamide'''
+
*'''[[PHA antivirals by mechanism]]'''
{{tp|p=32327293|t=ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |pdf=|usr=}}
+
  
'''Metronidazole''' retarget
+
*'''[[PHA pharmacophore by screened target]]'''
{{tp|p=32259129|t=2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen |pdf=|usr=}}
+
  
'''Glutathione GSH''' antioxidant
+
*'''[[PHA ImmunoNutrients]]
*[https://nypost.com/2020/05/09/new-york-mom-with-coronavirus-saved-by-medical-student-son/ found in a forrest gump mode]
+
*[https://www.sciencedirect.com/science/article/pii/S2213007120301350 Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases]
+
  
'''Chlorpromazine''' retarget
+
*'''[[PHA compl altern natural]]'''
*[https://www.biorxiv.org/content/10.1101/2020.05.05.079608v1 paper]
+
  
'''Zinc''' add-on
+
*'''[[PHA within indications compounds]]'''
*[https://www.sciencedirect.com/science/article/pii/S0306987720306435 call for trial]
+
  
'''Selenium'''
+
*'''[[PHA Serum products]]'''
{{tp|p=32342979|t=ä. Association between regional selenium status and reported outcome of COVID-19 cases in China |pdf=|usr=}}
+
  
'''Remdesivir''' retarget
+
*'''[[PHA Vaccination]]'''
*[https://gab.com/Remnant601/posts/104122987152232660 one hospital on...]
+
{{tp|p=32283108|t=ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites |pdf=|usr=}}
+
{{tp|p=32020029|t=2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |pdf=|usr=}}
+
  
'''Lauric acid''' nat. compd.
+
PHA related options:
*[https://www.icp.org.ph/2020/01/the-potential-of-coconut-oil-and-its-derivatives-as-effective-and-safe-antiviral-agents-against-the-novel-coronavirus-ncov-2019/ call for trial]
+
  
'''Nicotine''' nat. toxin
+
*[[Radiation therapy]]
*[https://www.usatoday.com/story/news/factcheck/2020/05/03/covid-19-fact-check-caution-urged-study-virus-smoking/3055378001/ france]
+
*[[Phototherapy]]
 +
*[[Electric fields]]
 +
*[[Treatment other concepts]]
  
'''Niclosamide'''
 
{{tp|p=32125140|t=ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |pdf=|usr=}}
 
  
'''Microbiome as target'''
+
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
{{tp|p=32356654|t=ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles |pdf=|usr=}}
+
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
'''ACE2 as target'''
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
{{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}}
+
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
{{tp|p=32333836|t=ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 |pdf=|usr=}}
+
based on e.g.
  
 +
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
  
'''Garlic extracts'''
+
=======================================================================================
{{tp|p=32363255|t=ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil |pdf=|usr=}}
+
  
'''Dipyridamole''' retarget
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32318327|t=ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 |pdf=|usr=}}
+
  
'''stem cells'''
+
  =======================================================================================
{{tp|p=32257554|t=2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia |pdf=|usr=}}
+
{{tp|p=32257537|t=2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia |pdf=|usr=}}
+
{{tp|p=32283815|t=2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use |pdf=|usr=}}
+
 
+
 
+
'''Ivermectin'''
+
{{tp|p=32330482|t=ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an  FDA warning, two letters to the editor and the authors  responses |pdf=|usr=}}
+
 
+
'''Various Leads'''
+
*[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone]
+
*[https://doi.org/10.1038/s41586-020-2286-9 paper in nature]
+
{{tp|p=32251767|t=2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |pdf=|usr=}}
+
 
+
 
+
'''Interferons'''
+
{{tp|p=32275914|t=2020. Type 1 interferons as a potential treatment against COVID-19 |pdf=|usr=}}
+
{{tp|p=32360182|t=2020. Antiviral activities of type I interferons to SARS-CoV-2 infection |pdf=|usr=}}
+
 
+
'''Plasmapheresis'''
+
 
+
'''Reconvalescent sera'''
+
{{tp|p=32243945|t=ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection |pdf=|usr=}}
+
 
+
'''Therapeutic antibodies (virus-targeted)'''
+
*[https://www.foxnews.com/science/man-made-antibody-neutralizes-coronavirus-first-time anti covid mab]
+
*[https://www.telegraaf.nl/nieuws/750205601/nederlands-antilichaam-47-d11-blokkeert-infectie-coronavirus acmab 47d11]
+
{{tp|p=32375025|t=ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain  Camelid Antibodies |pdf=|usr=}}
+
 
+
'''Therapeutic antibodies and biologicals (cytokine/sugnal transduction)'''
+
{{tp|p=32247642|t=ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report |pdf=|usr=}}
+
{{tp|p=32241793|t=2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies |pdf=|usr=}}
+
{{tp|p=32243501|t=2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab |pdf=|usr=}}
+
{{tp|p=32343968|t=ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report |pdf=|usr=}}
+
 
+
'''Glucocorticoids'''
+
 
+
{{tp|p=32149773|t=ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial |pdf=|usr=}}
+
 
+
'''CRISPR genome editing technology'''
+
{{tp|p=32353252|t=ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |pdf=|usr=}}
+
 
+
'''Virus interference'''
+
{{tp|p=32071427|t=2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses |pdf=|usr=}}
+
 
+
'''Other antirheumatic compounds'''
+
 
+
''Hydroxy-Chloroquine''
+
 
+
*check retina status; monitor rhythm known toxicity
+
*[https://justthenews.com/politics-policy/coronavirus/doctors-find-hydroxychloroquin-success-rate-91-urge-arizona-maybe-make 91% benefit]
+
*[https://www.themoscowtimes.com/2020/04/17/russia-approves-unproven-malaria-drug-to-treat-coronavirus-a70025 approval russia]
+
*[https://m.timesofindia.com/business/india-business/covid-19-68-new-companies-get-fdca-permit-to-make-hcq/amp_articleshow/75566317.cms scale up production]
+
*[https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf+html on safety, trial]
+
*[https://www.nejm.org/doi/full/10.1056/NEJMoa2012410?query=C19&cid=DM91569_NEJM_Registered_Users_and_InActive&bid=193180241 Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19] ''substance is useless.''
+
{{tp|p=32232419|t=ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know |pdf=|usr=}}
+
{{tp|p=32227189|t=ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 |pdf=|usr=}}
+
{{tp|p=32147496|t=2020. Of chloroquine and COVID-19 |pdf=|usr=}}
+
{{tp|p=32074550|t=2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies |pdf=|usr=}}
+
{{tp|p=32321905|t=2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database |pdf=|usr=}}
+
{{tp|p=32281583|t=2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32265182|t=2020. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review |pdf=|usr=}}
+
{{tp|p=32194981|t=2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro |pdf=|usr=}}
+
 
+
'''Chemoprevention Covid19'''
+
 
+
'''Antiviral agents Covid19'''
+
{{tp|p=32231345|t=2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high  capacity to mediate membrane fusion |pdf=|usr=}}
+
 
+
'''Lung regeneration and repair after Covid19'''
+
 
+
'''resilience enhancement'''
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32311498|t=ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
 
+
'''psychoneuroimmunology'''
+
{{tp|p=32234338|t=ä. Using psychoneuroimmunity against COVID-19 |pdf=|usr=}}
+
 
+
'''cannabinoids'''
+
{{tp|p=32360437|t=ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?|pdf=|usr=}}
+
 
+
 
+
'''Complementary & Traditional chinese medicine & Ethnopharm'''
+
{{tp|p=32245701|t=ä. Is traditional Chinese medicine useful in the treatment of COVID-19?|pdf=|usr=}}
+
{{tp|p=32233641|t=2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19 |pdf=|usr=}}
+
*[https://www.aa.com.tr/en/africa/madagascar-slams-who-for-not-endorsing-its-herbal-cure/1836905 madagascar herbs]
+
{{tp|p=32229706|t=2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?|pdf=|usr=}}
+
{{tp|p=32037389|t=2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment |pdf=|usr=}}
+
{{tp|p=32334064|t=ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet |pdf=|usr=}}
+
{{tp|p=32361935|t=ä. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32065348|t=ä. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs |pdf=|usr=}}
+
{{tp|p=32308732|t=2020. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China |pdf=|usr=}}
+
 
+
'''Exercise'''
+
{{tp|p=32311497|t=ä. The immunological case for staying active during the COVID-19 pandemic |pdf=|usr=}}
+
 
+
'''Topical agents''' opening up the world of nano...
+
*[https://www.dailymail.co.uk/sciencetech/article-8315269/Commercial-mouthwash-prevent-COVID-19-transmission-scientists-say.html on mouth rinses]
+
 
+
'''Anticoagulants'''
+
*[[Anticoagulant in covid19]]
+
 
+
'''Vaccination Covid19'''
+
{{tp|p=32105090|t=2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic |pdf=|usr=}}
+
*[https://patch.com/massachusetts/cambridge/ma-company-takes-critical-step-toward-covid-19-vaccine mrna-1273, moderna]
+
 
+
{{tp|p=32183941|t=2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for  Immune Responses to SARS-CoV-2 |pdf=|usr=}}
+
----
+
 
+
 
+
{{tp|p=32371558|t=2020. Hydroxychloroquine use in the COVID-19 patient |pdf=|usr=}}
+
{{tp|p=32272008|t=2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32337664|t=ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia |pdf=|usr=}}
+
{{tp|p=32359035|t=2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 |pdf=|usr=}}
+
{{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}}
+
{{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}}
+
{{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}}
+
{{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
+
{{tp|p=32353634|t=2020. COVID-19: Immunology and treatment options |pdf=|usr=}}
+
{{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}}
+
{{tp|p=32150618|t=ä. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |pdf=|usr=}}
+
{{tp|p=32211771|t=ä. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?|pdf=|usr=}}
+
{{tp|p=32211764|t=ä. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?|pdf=|usr=}}
+
{{tp|p=32266375|t=ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality |pdf=|usr=}}
+
{{tp|p=32255489|t=ä. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients |pdf=|usr=}}
+
{{tp|p=32301957|t=ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32344167|t=ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study |pdf=|usr=}}
+
{{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
+
{{tp|p=32306288|t=ä. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties |pdf=|usr=}}
+
{{tp|p=32277367|t=ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |pdf=|usr=}}
+
{{tp|p=32373721|t=2020. Low dose lung radiotherapy for COVID-19 pneumonia  The rationale for a cost-effective anti-inflammatory treatment |pdf=|usr=}}
+
{{tp|p=32269021|t=2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32209231|t=2020. Computers and viral diseases  Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus |pdf=|usr=}}
+
{{tp|p=32264963|t=2020. A new clinical trial to test high-dose vitamin C in patients with COVID-19 |pdf=|usr=}}
+
{{tp|p=32280433|t=ä. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model |pdf=|usr=}}
+
{{tp|p=32345336|t=2020. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32351851|t=ä. A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine |pdf=|usr=}}
+
{{tp|p=32241301|t=2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |pdf=|usr=}}
+
{{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}}
+
{{tp|p=32340837|t=ä. Hydroxychloroquine in Covid-19: Does the end justify the means?|pdf=|usr=}}
+
{{tp|p=32219057|t=ä. The SARS-CoV-2 Vaccine Pipeline: an Overview |pdf=|usr=}}
+
{{tp|p=32360420|t=ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia |pdf=|usr=}}
+
 
+
{{tp|p=32337328|t=2020. Coronaviruses: A patent dataset report for research and development (R&D) analysis |pdf=|usr=}}
+
{{tp|p=32247211|t=2020. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to  India and other developing countries |pdf=|usr=}}
+
{{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}}
+
{{tp|p=32333972|t=ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4  inhibition play a role?? |pdf=|usr=}}
+
{{tp|p=32333966|t=2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |pdf=|usr=}}
+
{{tp|p=32333969|t=ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too |pdf=|usr=}}
+
{{tp|p=32283128|t=ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?|pdf=|usr=}} ''on ace2 via adam17, nfkb via dpp4''
+
{{tp|p=32309622|t=ä. Emerging Therapeutic Strategies for COVID-19 patients |pdf=|usr=}}
+
{{tp|p=32336723|t=2020. Treatment of SARS-CoV-2: How far have we reached?|pdf=|usr=}}
+
{{tp|p=32321878|t=2020. Is GSK3beta a molecular target of chloroquine treatment against COVID-19?|pdf=|usr=}}
+
{{tp|p=32378648|t=2020. Rapid review for the anti-coronavirus effect of remdesivir |pdf=|usr=}}
+
{{tp|p=32378647|t=2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that  far?|pdf=|usr=}}
+
{{tp|p=32147628|t=2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32371138|t=ä. Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 |pdf=|usr=}}
+
{{tp|p=32198066|t=ä. Advance of promising targets and agents against COVID-19 in China |pdf=|usr=}}
+
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
{{tp|p=32320852|t=ä. Deja vu: Stimulating open drug discovery for SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32304645|t=ä. Boosting the arsenal against COVID-19 through computational drug repurposing |pdf=|usr=}}
+
{{tp|p=32266694|t=ä. Chloroquine for COVID-19 Infection |pdf=|usr=}}
+
{{tp|p=32373183|t=2020. Chloroquine and hydroxychloroquine in the context of COVID-19 |pdf=|usr=}}
+
{{tp|p=32343658|t=2020. Medication for COVID-19-an Overview of Approaches Currently Under Study |pdf=|usr=}}
+
{{tp|p=32344202|t=2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy  and vaccine development |pdf=|usr=}}
+
{{tp|p=32249203|t=ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and  rapid translational development |pdf=|usr=}}
+
 
+
{{tp|p=32379923|t=2020. Is BCG vaccination causally related to reduced COVID-19 mortality?|pdf=|usr=}}
+
{{tp|p=32333818|t=2020. COVID-19: lambda interferon against viral load and hyperinflammation |pdf=|usr=}}
+
{{tp|p=32338155|t=2020. Rheumotologitsts  view on the use of hydroxychloroquine to treat COVID-19 |pdf=|usr=}}
+
{{tp|p=32228222|t=2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension |pdf=|usr=}}
+
{{tp|p=32148172|t=2020. Timely development of vaccines against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=C7118608|t=ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System |pdf=|usr=}}
+
{{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}}
+
{{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pdf=|usr=}}
+
{{tp|p=32292627|t=ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment |pdf=|usr=}}
+
 
+
{{tp|p=32363880|t=2020. Medical treatment options for COVID-19 |pdf=|usr=}}
+
{{tp|p=32372695|t=2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol |pdf=|usr=}}
+
{{tp|p=32347925|t=ä. Statin therapy in COVID-19 infection |pdf=|usr=}}
+
{{tp|p=32347923|t=ä. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety |pdf=|usr=}}
+
{{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
+
{{tp|p=32282032|t=ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |pdf=|usr=}}
+
{{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
+
{{tp|p=C7129866|t=ä. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19 |pdf=|usr=}}
+
{{tp|p=32341100|t=2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective |pdf=|usr=}}
+
{{tp|p=32265310|t=ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19 |pdf=|usr=}}
+
{{tp|p=32271462|t=2020. Inositol and pulmonary function  Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}}
+
{{tp|p=32271456|t=2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease  2019 |pdf=|usr=}}
+
{{tp|p=32271454|t=2020. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19 |pdf=|usr=}}
+
{{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}}
+
{{tp|p=32329879|t=2020. (Naturlal products: )An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections |pdf=|usr=}}
+
{{tp|p=32327396|t=ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?|pdf=|usr=}}
+
{{tp|p=32279655|t=2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?|pdf=|usr=}}
+
{{tp|p=32250170|t=2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19?|pdf=|usr=}}
+
{{tp|p=32329380|t=2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia |pdf=|usr=}}
+
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}}
+
{{tp|p=32212513|t=2020. The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 COVID-19 and Its Research Progress in Forensic Toxicology |pdf=|usr=}}
+
{{tp|p=32269766|t=2020. In silico identification of vaccine targets for 2019-nCoV |pdf=|usr=}}
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis